| 前收盘价格 | 0.745 |
| 收盘价格 | 0.750 |
| 成交量 | 129,070 |
| 平均成交量 (3个月) | 394,584 |
| 市值 | 256,950,496 |
| 预期市盈率 (P/E Forward) | 40.32 |
| 价格/销量 (P/S) | 3.74 |
| 股市价格/股市净资产 (P/B) | 3.15 |
| 52周波幅 | |
| 利润日期 | 26 Nov 2024 |
| 营业毛利率 | -15.39% |
| 营业利益率 (TTM) | -13.37% |
| 稀释每股收益 (EPS TTM) | -0.020 |
| 季度收入增长率 (YOY) | 9.30% |
| 总债务/股东权益 (D/E MRQ) | 7.83% |
| 流动比率 (MRQ) | 7.26 |
| 营业现金流 (OCF TTM) | -7.38 M |
| 杠杆自由现金流 (LFCF TTM) | -11.84 M |
| 资产报酬率 (ROA TTM) | -5.86% |
| 股东权益报酬率 (ROE TTM) | -10.80% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (AU) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | AROA BIO FPO [ARX] | - | - |
AIStockmoo 评分
0.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.13 |
|
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 26.29% |
| 机构持股比例 | 21.72% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合